Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review

Zohre Momenimovahed , Afrooz Mazidimoradi , Leila Allahqoli , Zohre Khalajinia , Hamid Salehiniya , Ibrahim Alkatout

Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002316

PDF (1294KB)
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) :1002316 DOI: 10.37349/etat.2025.1002316
Systematic Review
research-article
Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review
Author information +
History +
PDF (1294KB)

Abstract

Background: Different tumor markers are utilized in the assessment of breast cancer. The function of these markers in assessing, tracking, and following up on breast cancer has drawn the interest of numerous researchers. Nonetheless, contradictory findings from research continue to raise questions regarding their effectiveness. Consequently, this research was carried out to evaluate the efficacy of carbohydrate antigen-125 (CA-125) in the treatment of breast cancer.

Methods: A thorough investigation was performed in the PubMed, Scopus, and Web of Science databases utilizing relevant keywords: CA-125, breast cancer, screening and diagnosis, and Mesh to locate articles published before August 2023 without any time limitations. The analysis included observational studies in English pertinent to the study’s objective, while review articles, case reports, editor letters, comments, and other reports were not considered. Articles were sought, examined, included, and evaluated according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analyses. The EndNote X9 program has been utilized for item management. The review included articles that investigated the predictive function of CA-125 in the screening, diagnosis, and anticipation for the early and proper detection of breast cancer.

Results: In the initial search, 1,475 articles were obtained. After screening and eligibility assessment, 33 studies were reviewed. Based on the findings of the studies, CA-125 can play a role in the diagnosis of breast cancer, its type and stage, early detection of recurrence and metastasis, treatment efficiency, prognosis, and survival rate. Discussion: The role of CA-125 as a biomarker for early detection, staging, and monitoring of recurrence and metastasis in breast cancer is still uncertain and needs additional research.

Keywords

CA-125 / prediction / screening / diagnosis / breast cancer

Cite this article

Download citation ▾
Zohre Momenimovahed, Afrooz Mazidimoradi, Leila Allahqoli, Zohre Khalajinia, Hamid Salehiniya, Ibrahim Alkatout. Utility of CA-125 for diagnosis and prognosis of breast cancer: a systematic review. Exploration of Targeted Anti-tumor Therapy, 2025, 6 (1) : 1002316 DOI:10.37349/etat.2025.1002316

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Allahqoli L, Mazidimoradi A, Momenimovahed Z, Rahmani A, Hakimi S, Tiznobaik A, et al. The Global Incidence, Mortality, and Burden of Breast Cancer in 2019: Correlation With Smoking, Drinking, and Drug Use. Front Oncol. 2022; 12: 921015.

[2]

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394-424.

[3]

Lei S, Zheng R, Zhang S, Wang S, Chen R, Sun K, et al. Global patterns of breast cancer incidence and mortality: A population-based cancer registry data analysis from 2000 to 2020. Cancer Commun (Lond). 2021; 41: 1183-94.

[4]

Calabrese A, Santucci D, Gravina M, Faiella E, Cordelli E, Soda P, et al. 3T-MRI Artificial Intelligence in Patients with Invasive Breast Cancer to Predict Distant Metastasis Status: A Pilot Study. Cancers (Basel). 2022; 15: 36.

[5]

Oshi M, Katsuta E, Yan L, Ebos JML, Rashid OM, Matsuyama R, et al. A Novel 4-Gene Score to Predict Survival, Distant Metastasis and Response to Neoadjuvant Therapy in Breast Cancer. Cancers (Basel). 2020; 12: 1148.

[6]

Barrios CH. Global challenges in breast cancer detection and treatment. Breast. 2022; 62: S3-6.

[7]

Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014; 5: 465-77.

[8]

Schliemann D, Hoe WMK, Mohan D, Allotey P, Reidpath DD, Tan MM, et al. Challenges and opportunities for breast cancer early detection among rural dwelling women in Segamat District, Malaysia: A qualitative study. PLoS One. 2022; 17: e0267308.

[9]

Allarakha A, Gao Y, Jiang H, Wang P. Prediction and prognosis of biologically aggressive breast cancers by the combination of DWI/DCE-MRI and immunohistochemical tumor markers. Discov Med. 2019; 27: 7-15.

[10]

Ai D, Yao J, Yang F, Huo L, Chen H, Lu W, et al. TRPS1: a highly sensitive and specific marker for breast carcinoma, especially for triple-negative breast cancer. Mod Pathol. 2021; 34: 710-9.

[11]

Zhang J, Wei Q, Dong D, Ren L. The role of TPS, CA125, CA15-3 and CEA in prediction of distant metastasis of breast cancer. Clin Chim Acta. 2021; 523: 19-25.

[12]

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372: n71.

[13]

Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A, Seilanian-Toosi M. Correlation of serum and salivary CA125 levels in patients with breast cancer. J Contemp Dent Pract. 2009; 10: E001-8.

[14]

Fang C, Cao Y, Liu X, Zeng X, Li Y. Serum CA125 is a predictive marker for breast cancer outcomes and correlates with molecular subtypes. Oncotarget. 2017; 8: 63963-70.

[15]

Gioia DD, Blankenburg I, Nagel D, Heinemann V, Stieber P. Tumor markers in the early detection of tumor recurrence in breast cancer patients: CA 125, CYFRA 21-1, HER2 shed antigen, LDH and CRP in combination with CEA and CA 15-3. Clin Chim Acta. 2016; 461: 1-7.

[16]

Norum LF, Erikstein B, Nustad K. Elevated CA 125 in Breast Cancer - A Sign of Advanced Disease. Tumour Biol. 2001; 22: 223-8.

[17]

Zhang J, Huang Y, Chen J, Wang X, Ma H. Potential of combination of DCE-MRI and DWI with serum CA125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer. World J Surg Oncol. 2021; 19: 284.

[18]

Chen W, Shen J, Zhou Y, Chen X, Liu J, Liu Z. Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep. 2017; 7: 11325.

[19]

Gaughran G, Aggarwal N, Shadbolt B, Stuart-Harris R. The Utility of the Tumor Markers CA15.3, CEA, CA-125 and CA19.9 in Metastatic Breast Cancer. Breast Cancer Management. 2020; 9: BMT50.

[20]

Ju L, Wang Y, Xie Q, Xu X, Li Y, Chen Z, et al. Elevated level of serum glycoprotein bifucosylation and prognostic value in Chinese breast cancer. Glycobiology. 2016; 26: 460-71.

[21]

Yerushalmi R, Tyldesley S, Kennecke H, Speers C, Woods R, Knight B, et al. Tumor markers in metastatic breast cancer subtypes: frequency of elevation and correlation with outcome. Ann Oncol. 2012; 23: 338-45.

[22]

Ma Y, Wang H, Zhao W, Li Y, Wang J, Chen X, et al. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer. Cancer Control. 2022; 29: 10732748211053150.

[23]

Lian M, Zhang C, Zhang D, Chen P, Yang H, Yang Y, et al. The association of five preoperative serum tumor markers and pathological features in patients with breast cancer. J Clin Lab Anal. 2019; 33: e22875.

[24]

Zhang Z, Chen G, Chen L. Correlation analysis on serum tumor markers of breast cancer patients with brain metastases and the clinicopathological factors. Life Science Journal. 2014; 11: 374-7.

[25]

Zhang S, Hu Y, Qian H, Jiao S, Liu Z, Tao H, et al. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer. Asian Pac J Cancer Prev. 2013; 14: 3937-40.

[26]

Yuan X, Song X, Jiang M, Li Q, Liu X, Wang M. Reproductive Factors, Steroid Receptor Status, and Tumour Markers of HER2-Positive Breast Cancer in Northern China. Breast Care (Basel). 2009; 4: 315-8.

[27]

Tang J, Yan B, Li G, Li Q, Liu W, Liang R, et al. Carbohydrate antigen 125, carbohydrate antigen 15-3 and low-density lipoprotein as risk factors for intraocular metastases in postmenopausal breast cancer. Medicine (Baltimore). 2021; 100: e27693.

[28]

Wang Y, Huang X, Mo M, Li J, Jia X, Shao Z, et al. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer. Asian Pac J Cancer Prev. 2015; 16: 4603-8.

[29]

Winden AWJO, Rodenburg W, Pennings JLA, Oostrom CTMv, Beijnen JH, Peeters PHM, et al. A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum. Int J Mol Sci. 2012; 13: 13587-604.

[30]

López-Jornet P, Aznar C, Ceron J, Asta T. Salivary biomarkers in breast cancer: a cross-sectional study. Support Care Cancer. 2021; 29: 889-96.

[31]

Nazmeen A, Maiti S, Mandal K, Roy SK, Ghosh TK, Sinha NK, et al. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease. Med Chem. 2017; 13: 796-804.

[32]

Luan Y, Wei J, Wang K, Cai D, Luo X, Fan W, et al. Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: A retrospective case-control study. Journal of Bio-X Research. 2021; 4: 60-6.

[33]

Luo J, Xiao J, Yang Y, Chen G, Hu D, Zeng J. Strategies for five tumour markers in the screening and diagnosis of female breast cancer. Front Oncol. 2023; 12: 1055855.

[34]

Feng C, Zhan Y, Shao H, Wang Z, Zhu S. Postoperative expressions of TRACP5b and CA125 in patients with breast cancer and their values for monitoring bone metastasis. J BUON. 2020; 25: 688-95.

[35]

Geng S, Fu S, Zhang H, Fu Y. Predictive nomogram based on serum tumor markers and clinicopathological features for stratifying lymph node metastasis in breast cancer. BMC Cancer. 2022; 22: 1328.

[36]

Kosmas C, Tsavaris NB, Soukouli G, Gouveris P, Tsakonas G, Katselis J, et al. Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer. Med Oncol. 2005; 22: 123-8.

[37]

Tornos C, Soslow R, Chen S, Akram M, Hummer AJ, Abu-Rustum N, et al. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. Am J Surg Pathol. 2005; 29: 1482-9.

[38]

Moritani S, Ichihara S, Hasegawa M, Endo T, Oiwa M, Yoshikawa K, et al. Serous papillary adenocarcinoma of the female genital organs and invasive micropapillary carcinoma of the breast. Are WT1, CA125, and GCDFP-15 useful in differential diagnosis? Hum Pathol. 2008; 39: 666-71.

[39]

Dong Y, Hou H, Wang C, Li J, Yao Q, Amer S, et al. The diagnostic value of18F-FDG PET/CT in association with serum tumor marker assays in breast cancer recurrence and metastasis. Biomed Res Int. 2015; 2015: 489021.

[40]

Lin Y, Fu F, Lin S, Qiu W, Zhou W, Lv J, et al. A nomogram prediction for the survival of patients with triple negative breast cancer. Oncotarget. 2018; 9: 32108-18.

[41]

Li X, Dai D, Chen B, He S, Zhang J, Wen C, et al. Prognostic Values Of Preoperative Serum CEA And CA125 Levels And Nomograms For Young Breast Cancer Patients. Onco Targets Ther. 2019; 12: 8789-800.

[42]

Li L, Gao Q, Xu G, Shi B, Ma X, Liu H, et al. Postoperative recurrence analysis of breast cancer patients based on clinical serum markers using discriminant methods. Cancer Biomark. 2017; 19: 403-9.

[43]

Fan S, Xie X, Shen Y, Wang W, Gu X, Yao Z. The predictive value of preoperative serum neutrophil-to-lymphocyte ratio and tumor markers for early breast cancer patients: A retrospective study. Medicine (Baltimore). 2022; 101: e30011.

[44]

Lou W. Correlation of CA125, CA153, and CEA levels in the diagnosis and prognosis of triple-negative breast cancer. Int J Clin Exp Med. 2020; 13: 3219-25.

[45]

Li J, Liu L, Feng Z, Wang X, Huang Y, Dai H, et al. Tumor markers CA15-3, CA125, CEA and breast cancer survival by molecular subtype: a cohort study. Breast Cancer. 2020; 27: 621-30.

[46]

Molina R, Barak V, Dalen Av, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer- European Group on Tumor Markers recommendations. Tumour Biol. 2005; 26: 281-93.

[47]

Riedinger J, Goussot V, Desmoulins I, Lorgis V, Coutant C, Beltjens F, et al. CEA and early detection of relapse in breast cancer subtypes: Comparison with CA 15-3. Bull Cancer. 2016; 103: 434-43.

[48]

Einama T, Yamagishi Y, Takihata Y, Suzuki T, Yamasaki T, Hirose Y, et al. Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients. Biomark Res. 2021; 9: 78.

[49]

Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021; 13: 4287.

[50]

Smolarz B, Nowak AZ, Romanowicz H. Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers (Basel). 2022; 14: 2569.

[51]

Zahedi A, Rafiemanesh H, Enayatrad M, Ghoncheh M, Salehiniya H. Incidence, Trends and Epidemiology of Cancers in North West of Iran. Asian Pac J Cancer Prev. 2015; 16: 7189-93.

[52]

Islami F, Sauer AG, Miller KD, Siegel RL, Fedewa SA, Jacobs EJ, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States. CA Cancer J Clin. 2018; 68: 31-54.

[53]

Islami F, Ward EM, Sung H, Cronin KA, Tangka FKL, Sherman RL, et al. Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics. J Natl Cancer Inst. 2021; 113: 1648-69.

[54]

Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for breast cancer in low-income and upper middle-income countries: a modelling study. Lancet Glob Health. 2018; 6: e885-93.

[55]

Caplan L. Delay in breast cancer: implications for stage at diagnosis and survival. Front Public Health. 2014; 2: 87.

[56]

Hutajulu SH, Prabandari YS, Bintoro BS, Wiranata JA, Widiastuti M, Suryani ND, et al. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. PLoS One. 2022; 17: e0262468.

[57]

Rivera-Franco MM, Leon-Rodriguez E. Delays in Breast Cancer Detection and Treatment in Developing Countries. Breast Cancer (Auckl). 2018; 12: 1178223417752677.

[58]

Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. Br J Cancer. 2013; 108: 2205-40.

[59]

Rahman S, Price JH, Dignan M, Rahman S, Lindquist PS, Jordan TR. Access to Mammography Facilities and Detection of Breast Cancer by Screening Mammography: A GIS Approach. Int J Canc Prev. 2009; 2: 403-13.

[60]

Vieira RAdC, Biller G, Uemura G, Ruiz CA, Curado MP. Breast cancer screening in developing countries. Clinics (Sao Paulo). 2017; 72: 244-53.

[61]

He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T, et al. A review on methods for diagnosis of breast cancer cells and tissues. Cell Prolif. 2020; 53: e12822.

[62]

Song Y, Yuan M, Wang G. Update value and clinical application of MUC16 (cancer antigen 125). Expert Opin Ther Targets. 2023; 27: 745-56.

[63]

Sharma T, Nisar S, Masoodi T, Macha MA, Uddin S, Akil AA, et al. Current and emerging biomarkers in ovarian cancer diagnosis; CA125 and beyond. Adv Protein Chem Struct Biol. 2023; 133: 85-114.

[64]

Tang Y, Cui Y, Zhang S, Zhang L. The sensitivity and specificity of serum glycan-based biomarkers for cancer detection. Prog Mol Biol Transl Sci. 2019; 162: 121-40.

[65]

Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol. 2003; 88: S152-7.

[66]

Kafali H, Artuc H, Demir N. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary report. Eur J Obstet Gynecol Reprod Biol. 2004; 116: 85-8.

[67]

Barooti E, Rashidi Fakari F, Darvish S, Tavakoly N. The Comparison of CA125 Levels in the Normal Pregnancy and Threatened Abortion. J Obstet Gynecol Cancer Res. 2022; 7: 226-9.

[68]

Edula RG, Muthukuru S, Moroianu S, Wang Y, Lingiah V, Fung P, et al. CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol. 2018; 6: 241- 6.

[69]

Castillo Velarde ER. Cancer Antigen 125 and Nephrotic Syndrome. World J Nephrol Urol. 2019; 8: 14-6.

[70]

Kabel AM. Tumor markers of breast cancer: New prospectives. J Oncol Sci. 2017; 3: 5-11.

[71]

Bilen MA, Reyes A, Bhowmick D, Maa A, Jr RB, Pisters LL, et al. Variant prostate carcinoma and elevated serum CA-125. Can J Urol. 2014; 21: 7442-8.

[72]

Saad HM, Tourky GF, Al-Kuraishy HM, Al-Gareeb AI, Khattab AM, Elmasry SA, et al. The Potential Role of MUC16 (CA125) Biomarker in Lung Cancer: A Magic Biomarker but with Adversity. Diagnostics (Basel). 2022; 12: 2985.

[73]

Björkman K, Mustonen H, Kaprio T, Kekki H, Pettersson K, Haglund C, et al. CA125: A superior prognostic biomarker for colorectal cancer compared to CEA, CA19-9 or CA242. Tumour Biol. 2021; 43: 57-70.

[74]

Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 2019; 12: 28.

[75]

LyBarger KS, Miller HA, Frieboes HB. CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting. Sci Rep. 2022; 12: 19783.

[76]

Honda K, Miyama M, Nishii Y, Tasaka R, Nakano Y, Umesaki N, et al. Metastasis of cervical cancer indicated by elevation of serum CA125 produced by mediastinal lymph nodes: a case report. J Med Case Rep. 2024; 18: 112.

[77]

Liu L, Xu H, Wang W, Wu C, Xiang J, Liu C, et al. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden. Oncotarget. 2016; 7: 5943-56.

[78]

Memar B, Aledavood A, Shahidsales S, Ahadi M, Farzadnia M, Raziee HR, et al. The Prognostic Role of Tumor Marker CA-125 in B-Cell non-Hodgkin’s Lymphoma. Iran J Cancer Prev. 2015;8:42-6.

[79]

Zhan CH, Liu GJ. Diagnostic Value of a Combined Serum α-Hydroxybutyrate Dehydrogenase, Carcinoembryonic Antigen and Glycoantigen 125 Test for Early-Stage Breast Cancer. Targets and Therapy. 2023; 15: 617-23.

[80]

Chen R, Jiang C, Zhu Q, You S, Li Y, Li S, et al. Combining the tumor abnormal protein test with tests for carcinoembryonic antigens, cancer antigen 15-3, and/or cancer antigen 125 significantly increased their diagnostic sensitivity for breast cancer. Medicine (Baltimore). 2020; 99: e21231.

[81]

Wang W, Xu X, Tian B, Wang Y, Du L, Sun T, et al. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer. Clin Chim Acta. 2017; 470: 51-5.

[82]

Kandylis K, Vassilomanolakis M, Baziotis N, Papadimitriou A, Tsoussis S, Ferderigou A, et al. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer. Ann Oncol. 1990; 1: 435-8.

[83]

Andreucci M, Solomon R, Tasanarong A. Side effects of radiographic contrast media: pathogenesis, risk factors, and prevention. Biomed Res Int. 2014; 2014: 741018.

[84]

Hwang S, Choi E, Kim Y, Gim B, Ha M, Kim H. Health effects from exposure to dental diagnostic X-ray. Environ Health Toxicol. 2018; 33: e2018017.

[85]

DeLouize AM, Eick G, Karam SD, Snodgrass JJ. Current and future applications of biomarkers in samples collected through minimally invasive methods for cancer medicine and population-based research. Am J Hum Biol. 2022; 34: e23665.

[86]

Varzaru VB, Eftenoiu AE, Vlad DC, Vlad CS, Moatar AE, Popescu R, et al. The Influence of Tumor-Specific Markers in Breast Cancer on Other Blood Parameters. Life. 2024; 14: 458.

[87]

Singh J, Kaur S, Singh D. Comparative study of biomarkers in diagnosed cases of breast cancer. JCDR. 2024; 15: 3937-40.

[88]

Ertl I, Heinemann V, Laessig D, Nagel D, Seidel D, Stieber P. CA 125 in the early detection of metastatic breast cancer. J Clin Oncol. 2009; 27: e12015.

PDF (1294KB)

0

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉